Merz Pharma Group (www.merz.com) has acquired Neocutis S.A.’s privately held cosmetics, OTC and Rx skincare business. The acquisition, which closed on July 22, 2013, will be managed in North America by Merz Pharma Group’s U.S. affiliate, Merz North America, which will also integrate marketing of Neocutis’ line of physician-dispensed topical skin care products in the U.S.
“The acquisition of Neocutis significantly strengthens Merz’s presence in the U.S. aesthetics market,” said Bill Humphries, president and CEO of Merz North America. “Neocutis’ line of topical skincare products complements our current portfolio of aesthetic injectable products and expands our ability to provide patients and physicians with innovative, high-quality aesthetic products along the full continuum of care. We are excited to welcome the Neocutis team to the Merz family; we look forward to learning from them and seeing their contributions to our continued growth in North America.”